Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 624

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 624
---
ger (the “ FutureTech II Merger Agreement”) with FutureTech II, a blank-check special purpose acquisition company. Pursuant to the FutureTech II Merger Agreement, the parties thereto will enter into a business combination transaction (the “Business Combination” and together with the other transactions contemplated by the FutureTech II Merger Agreement, the “Transactions”), pursuant to which, among other things, (i) Longevity will consummate the Acquisition Transactions upon the terms and subject to conditions set forth therein and pursuant to the C&E Agreements, and (ii) immediately following the consummation of the Acquisition Transactions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the FutureTech II. At the closing of the Transactions (“Closing”), FutureTech II will change its name to Longevity Biomedical, Inc., and its common stock is expected to list on Nasdaq under the ticker symbol “LBIO.”

The aggregate consideration to be paid to the holders of Longevity common stock, par value $0.0001 per share (the “Longevity Common Stock”), at the Closing will consist of a number of shares of FutureTech II common stock, par value $0.0001) equal to (a) (i) $100,000,000 minus (ii) the value of each outstanding option (whether vested or unvested) to purchase Longevity Common Stock that is converted into a new FutureTech II options in accordance with the Merger Agreement, divided by (b) $10.00.

The consummation of the FutureTech II Merger Transactions are subject to the satisfaction or waiver of certain customary closing conditions contained in the FutureTech II Merger Agreement, including, among other things, requisite approval by FutureTech II’s shareholders.

Note 10 - Subsequent Events

The Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this evaluation, the Company did not identify any subsequent events that would have required adjustment or disclosure in these financial statements.

| F-102 |

<div align='center'>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

To the Shareholders and Board of Directors of

Cerevast Medical, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Cerevast Medical, Inc